Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | CCNH | P51946 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12075159 | 0.74 | MKNK1 (0.46) | MKNK1MKNK2MAPK8MAPK9MAPK10 | |
| SCHEMBL2189180 | 0.72 | HRH3 (0.44) | MKNK1MKNK2MAPK8MAPK9MAPK10 | |
| SCHEMBL3873515 | 0.72 | RAB9A (0.57) | MAPK8MAPK9MAPK10CCNE1CDK2 | |
| SCHEMBL5617548 | 0.72 | MAPK8 (0.40) | MKNK1MKNK2MAPK8MAPK9MAPK10 | |
| SCHEMBL29539072 | 0.71 | CYP11B2 (0.44) | MKNK1MKNK2CYP11B1CYP11B2LRRK2 | |
| SCHEMBL6594548 | 0.71 | CDC7 (0.47) | MKNK1MKNK2MAPK8MAPK9MAPK10 | |
| SCHEMBL31020506 | 0.70 | IRAK4 (0.57) | MKNK1MKNK2MAPK8MAPK9MAPK10 | |
| SCHEMBL12075537 | 0.70 | IRAK4 (0.57) | MKNK1MKNK2MAPK8MAPK9MAPK10 | |
| SCHEMBL21801556 | 0.70 | LRRK2 (0.43) | MKNK1MKNK2MAPK8MAPK9MAPK10 | |
| Hydrochloric Acid SCHEMBL30557140 | 0.70 | CYP11B2 (0.43) | MKNK1MKNK2CYP11B1CYP11B2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114573567-A | Indazole cyclic triazole compound and preparation method and application thereof | 西安交通大学 | 2022-06-03 | — | — | CN | claimed |
| CN-114437113-A | Thiazolopyridine ring-linked triazole compound and preparation method and application thereof | 西安交通大学 | 2022-05-06 | — | — | CN | claimed |
| US-20260042753-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2026-02-12 | — | — | US | disclosed |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | KAINOS MEDICINE, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12486260-B2 | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | MERCK PATENT GMBH (DE) | 2025-12-02 | — | — | US | disclosed |
| EP-4520326-A2 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | Merck Patent GmbH (DE) | 2025-03-12 | — | — | EP | disclosed |
| CN-114466844-B | N- (1H-imidazol-2-yl) benzamide compound and pharmaceutical composition comprising same as active ingredient | 康佳诺医疗科技发展有限公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-3924340-B1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2025-01-29 | — | — | EP | disclosed |
| CN-118955486-A | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | 默克专利股份公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-113474334-B | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | 默克专利股份公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-114573567-B | Indazole cyclotriazole compound and preparation method and application thereof | 西安交通大学 | 2023-05-02 | — | — | CN | disclosed |
| US-20180319795-A1 | THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r) | NORTHWESTERN UNIVERSITY (US) | 2018-11-08 | — | — | US | disclosed |
| US-10059708-B2 | Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r) | NORTHWESTERN UNIVERSITY (US) | 2018-08-28 | — | — | US | disclosed |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS INC (CA) | 2018-03-15 | — | — | US | disclosed |
| US-20170305901-A1 | THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r) | NORTHWESTERN UNIVERSITY (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2017075052-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2017-05-04 | — | — | WO | disclosed |
| CN-103429585-B | Indazolyl triazole derivatives as interleukin-1 receptor associated kinase inhibitors | MERCK SERONO SA | 2015-07-08 | — | — | CN | disclosed |
| CN-103429585-B | Indazolyl triazole derivatives as interleukin-1 receptor associated kinase inhibitors | MERCK SERONO SA | 2015-07-08 | — | — | CN | disclosed |
| CN-103429585-A | Indazolyl triazole derivatives as interleukin-1 receptor associated kinase inhibitors | MERCK SERONO SA | 2013-12-04 | — | — | CN | disclosed |
| CN-103429585-A | Indazolyl triazole derivatives as interleukin-1 receptor associated kinase inhibitors | MERCK SERONO SA | 2013-12-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10059708-B2 | Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r) | IRAK4, IRAK1, IRAK2 | MKNK1 91/4885MKNK2 205/4885MAPK8 397/4885 |
| US-20260042753-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | KIT, ABL1, DSTYK | MKNK1 1006/4885MKNK2 1055/4885MAPK8 954/4885 |
| US-20180319795-A1 | THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r) | IRAK4, IRAK1, IRAK2 | MKNK1 84/4885MKNK2 207/4885MAPK8 414/4885 |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | MKNK1 517/4885MKNK2 432/4885MAPK8 510/4885 |
| US-20170305901-A1 | THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r) | IRAK4, IRAK1, IRAK2 | MKNK1 84/4885MKNK2 207/4885MAPK8 414/4885 |
| US-12486260-B2 | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | KIT, TNNI3K, CILK1 | MKNK1 178/4885MKNK2 154/4885MAPK8 512/4885 |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | IRAK4, IRAK1, IRAK2 | MKNK1 2469/4885MKNK2 2325/4885MAPK8 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.